Previous 10 | Next 10 |
Dynavax Technologies ( NASDAQ: DVAX ) is up 8% in after-hours trading after upping its 2022 guidance for revenue of its key product, the vaccine adjuvant CpG 1018. The company now expects 2022 sales of CpG 1018 of $550M-$600M. In May, it was projected at $550M. CpG...
Dynavax press release ( NASDAQ: DVAX ): Q2 GAAP EPS of $0.87 beats by $0.65 . Revenue of $256.46M (+386.0% Y/Y) beats by $105.47M . Cash and Marketable Securities. Cash and marketable securities were $518.2 million as of June 30, 2022. 2022 Financial ...
Dynavax Reports Second Quarter 2022 Financial Results PR Newswire Q2 2022 total revenue of $256.5 million , up 386% from $52.8 million for Q2 2021 HEPLISAV-B ® vaccine net product revenue of $32.7 million, up 139% fro...
One key metric that allows us to see under the surface of the market is “relative strength”, or how well a stock is faring against other stocks in the same market space. (1) This method helped William O’Neil become an investing legend (2), and the CANSLIM approach he foun...
Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022 PR Newswire EMERYVILLE, Calif. , July 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company ...
The European Commission announced an agreement with Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) ( OTC:VNVLF ) on Wednesday that would sharply reduce the French biotech’s COVID-19 vaccine deliveries to the region this year. In late June, the commission approved ...
As of June 30, 2022, AAII’s Oberweis Octagon screening model has an annual gain since inception (1998) of 11.4%. The AAII Oberweis Octagon strategy seeks rapidly growing small- to mid-size companies trading at attractive prices. The Oberweis Octagon screen seeks to identify...
Previously overbought and overvalued, many Growth/Tech stocks have gotten creamed in 2022. With the recent decline in inflation expectations and by extension long-term yields, this area of the market is getting some relief. In addition to that macro-related consideration, the char...
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones. Shanghai Zai Lab has changed its Hong Kong listing from secondar...
Clover Biopharmaceuticals said that a third dose of its COVID-19 vaccine showed neutralizing antibody levels against Omicron variants in a trial. Clover noted that it created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax Technologies (NASDAQ:DVAX) CpG 1018 advanc...
News, Short Squeeze, Breakout and More Instantly...
Dynavax Technologies Corporation Company Name:
DVAX Stock Symbol:
NASDAQ Market:
Dynavax Technologies Corporation Website:
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 PR Newswire EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company dev...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program PR Newswire EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing inn...
2024-06-21 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...